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Abstract
Background: Optimising the management of peri-operative pain and recovery following knee replacement has
been identified as a patient priority. Current pain relief strategies use opiate-based analgesia; however, up to 50% of
patients experience significant side effects. Local anaesthetic incisional infiltration is one alternative. The length of
the duration of action is a major limiting factor of current local anaesthetic techniques. Liposomal bupivacaine has
been reported to be effective for up to 72 h. This randomised controlled trial will evaluate the clinical and cost
effectiveness of liposomal bupivacaine.
Methods: SPAARK is a patient-blinded, multi-centre, active comparator, superiority, two-arm, parallel-group randomised
controlled trial. Five hundred patients undergoing knee replacement will be recruited and randomised to liposomal
bupivacaine plus bupivacaine hydrochloride or bupivacaine hydrochloride alone. The co-primary outcomes are the Quality of
Recovery 40 measured at 72 h post-surgery and also cumulative pain measured daily using a 0–10 visual analogue scale for
the first 3 days following surgery. Secondary outcomes include cumulative opioid consumption, fitness for discharge,
functional outcomes assessed using the Oxford Knee Score and American Knee Society Score, the EuroQol five dimensions
instrument and complications. A cost utility analysis is also planned.
Discussion: The clinical effectiveness and cost effectiveness of liposomal bupivacaine have yet to be evaluated
in the National Health Service, making this trial appropriate and timely.
Trial registration: ISRCTN registry, ISRCTN54191675. Registered on 14 November 2017.
Keywords: Randomised controlled trial, Knee replacement, Liposomal bupivacaine, Anaesthetic, Analgesia, Peri-
operative pain
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Background
Around 100,000 primary knee replacements are per-
formed in the UK every year, and this number is increas-
ing. Similar trends are likely to be seen worldwide, with
the number of primary total knee arthroplasties predicted
to rise to 3.48 million procedures by 2030 [1]. Optimising
the management of peri-operative pain and recovery has
been identified as a patient priority [2]. Improving post-
operative recovery has many benefits both to the patient
in terms of reduced morbidity and mortality and the
healthcare system through reduced healthcare-associated
costs [3]. Current pain relief strategies post-knee replace-
ment surgery use opiate-based analgesia. However, up to
50% of patients experience significant side effects, such as
nausea, vomiting and drowsiness [4]. Opioid-sparing tech-
niques have been associated with enhanced patient satis-
faction post-surgery [5]. There is increasing evidence
about their longer term benefits, with studies reporting a
lowered incidence of chronic post-surgical pain, though
the full effect on long-term patient-reported outcome
measures is unknown [6–8].
The concept of multi-modal analgesia was introduced
more than 20 years ago, and its use has expanded to many
areas of surgery, including knee replacement surgery [9].
Local anaesthetic incisional infiltration is commonly used
as part of this technique with the view that modification
of pain stimuli at their origin will reduce the transmission
of nociceptive stimuli. The length of their duration of ac-
tion is a major limiting factor of current local anaesthetic
techniques, and despite multi-modal techniques, a signifi-
cant number of patients report severe post-operative pain
following knee replacement. Current methods to address
this remain unsatisfactory due to the increased risk of in-
fection, interference with early mobilisation and discharge
caused by the use of an indwelling infiltration catheter as
well as the additional cost of infusion devices. Due to the
inherent benefits of having a longer acting local anaes-
thetic, a great deal of interest has been invested in the de-
velopment of a new drug: liposomal bupivacaine.
Liposomal bupivacaine (Exparel, Pacira Pharmaceuticals,
Inc., San Diego, CA, USA) is liposome-encapsulated bupi-
vacaine, which has been reported to be effective for up to
72 h [10, 11]. Using a proprietary technique known as
DepoFoam (SkyePharma, London, UK), the local anaes-
thetic bupivacaine is held within multi-vesicular liposomes
which permit prolonged release through diffusion, mem-
brane breakdown and re-organisation [12].
Previous studies using liposomal bupivacaine show
that some patients were discharged on the day of surgery
following hip and knee replacement procedures with no
reported incidents of increased re-admission rates or
wound issues [13–15].
These studies also show that liposomal bupivacaine is
well tolerated and has been reported to be associated
with significantly lower pain scores, opiate usage and
opiate-related adverse effects as well as a reduced length
of stay. Liposomal bupivacaine has also been reported to
be cost effective in gastrointestinal and orthopaedic joint
surgery in the USA [13]. The clinical effectiveness and
cost effectiveness of liposomal bupivacaine have yet to
be evaluated in the National Health Service (NHS), mak-
ing this trial appropriate and timely.
Methods/design
Trial design
The Study of Peri-Articular Anaesthetic for Replacement
of the Knee (SPAARK) is a patient-blinded, multi-centre,
active comparator, superiority, two-arm, parallel-group
randomised controlled trial. The aim of SPAARK is to
evaluate the clinical and cost-effectiveness of liposomal
bupivacaine with bupivacaine hydrochloride compared
to bupivacaine hydrochloride alone on post-operative re-
covery after knee replacement surgery. Eligible patients
listed for knee replacement will be randomised to either
liposomal bupivacaine plus bupivacaine hydrochloride or
bupivacaine hydrochloride alone. Randomisation will be
performed using a secure on-line Internet-based system
(RRAMP) provided by the Oxford Clinical Trials Re-
search Unit (OCTRU).
Patients will be randomised 1:1 to the two treatment
groups using stratified randomisation with variable block
sizes, stratified by recruitment centre and surgical pro-
cedure (total knee replacement (TKR) or unicompart-
mental knee replacement (UKR). The co-primary
outcome measures for SPAARK are cumulative pain,
measured daily using a 0–10 visual analogue scale (VAS)
for the first 3 days post-surgery, summarised using the
area under the curve, and Quality of Recovery 40 (QoR-
40) score measured at 72 h. Further follow-up assess-
ments with patient-reported questionnaires will be per-
formed 6 weeks after surgery and 6 and 12 months after
randomisation. These include the Oxford Knee Score
(OKS), the patient-reported section of the American
Knee Society Score (AKSS), a health resource use ques-
tionnaire and the EuroQol five levels of severity and five
dimensions instrument (EQ-5D-5 L). Data on adverse
events is also collected from sites and participants.
The protocol conforms to the Standard Protocol
Items: Recommendations for Interventional Trials
(SPIRIT) guidelines [16]. The SPIRIT checklist is pro-
vided as Additional file 1. The data collected at each
time point will be as described in Table 1.
Trial setting
Five hundred participants will be recruited from ap-
proximately ten sites across the UK. The number of
recruiting centres may be increased as the study pro-
gresses. The recruiting centres are a mix of district
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general hospitals and specialist centres from a range of
regions across England.
Inclusion criteria
The participant may enter the trial if all of the following
apply:
 Has had unilateral primary knee replacement,
including both TKR and UKR, for end-stage
osteoarthritis
 Has American Society of Anesthesiologists (ASA)
physical status grades I to III
 Is willing and able to consent for himself/herself
 Is male or female, aged 18 years or older
 In the Investigator’s opinion, is able and willing to
comply with all trial requirements.
Exclusion criteria
The participant may not enter the trial if any of the fol-
lowing apply:
 Allergy or intolerance to amide-type local
anaesthetics
 Objective evidence of nerve damage in the affected
lower limb
 Rheumatoid arthritis
 Any other significant disease, disorder or condition
which, in the opinion of the Investigator, may either
put the participants at risk because of participation
in the trial, or may influence the results of the trial
or the participant’s ability to participate in the trial
 Participation in another research trial involving an
investigational product in the past 6 months
 Patients who have significant cognitive impairment
or language issues
 Contra-lateral knee replacement within the trial or
within 12 months prior to randomisation.
Outcomes
The co-primary outcomes in this trial are cumulative
pain, measured daily using a 0–10 VAS for the first 3
days following surgery, and the QoR-40 at 72 h. The
QoR-40 is a global measure of quality of recovery. It in-
corporates five dimensions of health: patient support,
comfort, emotions, physical independence and pain;
each item is graded on a 5-point Likert scale. QoR-40
scores range from 40 (extremely poor quality of recov-
ery) to 200 (excellent quality of recovery). Pain will be
measured using a 0–10 VAS [17] on the evening of sur-
gery and once daily on the following 3 days. Where pos-
sible, these assessments will be made at the same time
each day, though this time may depend on when the
participant receives his/her surgery. Cumulative pain up
to 3 days post-surgery will be calculated as the area
under the curve for each participant using the summary
measures approach [18].
Table 1 Summary of outcomes and assessment schedule
















Summary medical history X
Summary medication history X X X X
QoR-40 X X X X X X X X
Pain VAS at rest X X X X X X X X
Cumulative opioid consumption X X X X
Fitness for discharge X X X X
Oxford Knee Score X X X X
American Knee Society Score X X X X
Patient expectations X X X X
EQ-5D-5 L X X X X X X X X
Summary healthcare/social services use and informal care due to
knee
X X X X
Summary employment history X X X X
Treatment X
Knee replacement procedure details X
Administration of investigational medicinal product X
Complications X X X X X
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The secondary outcome measures in this trial are as
follows:
 Cumulative opioid consumption over 72 h after
surgery: all opioids used on evening of surgery (day
0) and on days 1, 2 and 3 will be recorded and a
running total of cumulative opioid use calculated.
 Fitness for discharge will be assessed against pre-
defined criteria and collected daily until discharge.
Patients will be considered fit for discharge when
they meet four criteria: (1) ability to mobilise inde-
pendently; (2) pain score less than or equal to 3 cm
on a 10 cm VAS; (3) ability to perform straight leg
raise; (4) ability to bend knee to 90 degrees.
 Oxford Knee Score (OKS): a 12-item patient-
reported outcome measure designed to measure
pain and function after knee replacement surgery
[19]. Each question is scored from 0 (“none”, mean-
ing no pain, usually in knee) to 4 (“severe” pain, usu-
ally in knee). A total score is obtained by summing
across all 12 items to give a single score with a range
from 0 (best score) to 48 (worst score).
 American Knee Society Score (AKSS): Symptoms,
Satisfaction, Expectations, Functional Activities. The
“Symptoms” category contains two 10-level scales,
ranging from “none to “severe” for patients to rate
their pain for walking on level ground and on stairs/
inclines. There is an additional question regarding
how “normal” the knee feels to the patient. “Patient
Satisfaction” is a five-question, 40-point scale, and
“Patient Expectations” is a three-question, 15-point
scale that is collected pre-operatively (at baseline)
and post-operatively (up to 72 h after surgery, 6
weeks after surgery and 6 and 12 months after ran-
domisation). The pre-operative questions reflect pa-
tients’ opinions on the extent to which they expect
that the operation will improve their knee pain and
their ability to perform their activities of daily living
and recreational activities. The post-operative ques-
tions reflect the extent to which the outcome after
the operation has met the patient’s pre-operative ex-
pectations with respect to pain and function. The
“Functional Score” comprises four subgroups (Walk-
ing and Standing, Standard Activities, Advanced Ac-
tivities and Discretionary Activities). The maximum
score is 100 [20].
 Cost utility analysis using patient-reported quality
of life as the main outcome, obtained using the
EuroQol EQ-5D-5 L questionnaire [21] at base-
line, on the evening of surgery (day 0), days 1, 2
and 3 following surgery and at 6 weeks and 6 and
12 months.
 Complications: serious adverse events (SAEs),
specifically cardiovascular or wound complications
within 30 days of surgery. These will be recorded
using the Clavien-Dindo Classification [22].
Data management will be performed via a web-based,
bespoke trial database (OpenClinica). OpenClinica is a
dedicated and validated clinical trials database designed
for electronic data capture.
Recruitment
All patients listed for knee replacement, i.e. TKR and
UKR, for end-stage osteoarthritis will be eligible. We ex-
pect to recruit a maximum of 10% of patients listed for
UKRs, as this would reflect current practice in the UK.
The number of UKRs recruited will not be restricted;
however, the proportion of procedures of each type will
be reported by treatment group. Patients will be identi-
fied at outpatient clinics by participating surgeons and
their clinical care team. Potential patients may also be
identified by the clinical team from surgical waiting lists.
Informed consent will be taken by a medically qualified
and suitably experienced investigator. Consent will be
verbally re-confirmed on the day of surgery. Due to local
patient pathways, informed consent and baseline assess-
ments may be completed at the same hospital visit; how-
ever, it may be the case that randomisation is not
performed on the same day. Where possible, randomisa-
tion will occur on the day of surgery either by a member
of the clinical research team or a member of the surgical
team. Where this is not possible, randomisation may
occur on the days prior to surgery. Patients will be
blinded to the treatment allocation. Surgeons and anaes-
thetists will not be blinded. Un-blinding will be per-
formed on an individual basis as clinical need dictates.
Interventions
The trial drug is 266 mg liposomal bupivacaine. In the
intervention arm, the liposomal bupivacaine is admixed
with 100 mg of plain bupivacaine hydrochloride. Plain
bupivacaine hydrochloride is included alongside the in-
vestigational treatment to ensure pain relief in the im-
mediate post-operative period for these patients. In the
control arm, 100mg bupivacaine hydrochloride is ad-
ministered alone. In both arms, the volume is expanded
to 120 ml with normal saline and administered as a sin-
gle dose intra-operatively by peri-articular infiltration.
The surgeons will be trained in the administration
technique, and a guide to the technique will be provided
in each operating theatre. With the exception of the trial
drug or active control, the pre-, intra- and post-
operative analgesia regimes and management will follow
local protocols. Peri-operative pain and rehabilitation
pathways are not standardised across study sites. They
vary across hospitals and may include a variety of
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regimens, including scheduled opioids and additional
nerve blocks, per provider discretion.
Surgeons will be asked about their compliance with
the intervention procedure following treatment of each
participant.
Withdrawals
Each participant has the right to withdraw from any as-
pect of the trial at any time. For many reasons, patients’
operations may be cancelled, or patients may withdraw
themselves from the surgical waiting list. If patients have
been randomised and then do not go on to have surgery,
reasons for cancellation will be recorded. If patients are
willing, they will continue to be followed up. If a partici-
pant withdraws from the follow-up regime, data up to
the point of withdrawal will be collated and analysed
accordingly.
Safety
Reporting of complications or adverse events
Within 30 days of the surgery, adverse events need to be
recorded if there is a reasonable possibility they are re-
lated to the administration of the investigational medi-
cinal product (IMP), the control drug or the knee
replacement surgery. Common examples of such events
include nausea, constipation and vomiting. If the event
is deemed to be serious (i.e. it meets the SAE criteria),
then this will be reported on a SAE form. SAEs must be
reported throughout the duration of the study and
follow-up period (12 months from randomisation). The
sites must notify the study office in Oxford of these
events within 24 h following knowledge of the event.
All patient deaths, regardless of cause/relatedness, will
be reported on the SAE form.
The Reference Safety Information (RSI) (US prescrib-
ing information, found at www.dailymed.nlm.nih.gov)
lists all known expected adverse reactions in relation to
the administration of the trial drug (liposomal bupiva-
caine). The Summary of Product Characteristics (SmPC)
lists all known adverse drug reactions for the control
drug (bupivacaine hydrochloride). The assessment of ex-
pectedness will be done centrally, independent of the site
Principal Investigator, and will be performed against
what is documented in the RSI or SmPC.
Statistics and analysis
Sample size
The trial has been powered for two primary endpoints,
QoR-40 at 72 h and cumulative pain score from 6 to 72
h, with adjustment for multiplicity using the Bonferroni
method [23]. The trial will be assessed as providing evi-
dence of a difference if either of the two primary end-
points is statistically and clinically significant.
The study requires 480 patients (240 per treatment
arm) in order to be 90% powered to detect a 5-point dif-
ference in global QoR-40 score between groups at a sig-
nificance level of 0.025 (two-sided, adjusted for
multiplicity) assuming that the standard deviation is 15.5
[24]. To allow for 4% loss to follow-up, this has been in-
flated to 500 patients (250 per treatment arm).
The study also requires a minimum of 225 patients
per treatment arm in order to be 90% powered to detect
a standardised difference of 33% between groups in cu-
mulative pain score calculated as area under the curve
from 6 to 72 h post-surgery at a significance level of
0.025 (two-sided, adjusted for multiplicity). Inflating the
sample size to 500 patients (250 per treatment arm) will
allow for 10% loss to follow-up on this variable.
Therefore, a total of 500 patients will be randomised
(250 per arm).
Statistical analysis
The primary objective of improved patient recovery will
be assessed by analysing the two primary endpoints: global
QoR-40 score at 72 h and cumulative pain score from 6 to
72 h following surgery. The null hypothesis that there is
no difference between the treatment arms will be rejected
if either of these dual primary outcomes is statistically dif-
ferent at the two-sided 2.5% significance level.
Both of the primary outcomes will be analysed using
multi-variate linear regression adjusting for stratification
factors and other important prognostic variables, includ-
ing baseline scores in the case of the QoR-40. The ad-
justed mean difference between the two groups together
with 97.5% confidence intervals will be reported for each
of the primary outcomes. If either of the primary out-
comes is not normally distributed, an appropriate trans-
formation to normality will be the first approach. The
transformation selected will depend on the departure from
normality observed. If this is not possible, then non-
parametric techniques without adjustment will be used.
As secondary analyses, both pain and QoR-40 measured
at 6, 24, 48 and 72 h will be assessed using longitudinal
methods to take account of the multiple time points and
the correlation between them. Multi-level, multi-variate
linear regression modelling with adjustment for the same
factors as the primary analysis will be used. Other con-
tinuous variables will be analysed using a similar method-
ology. For binary variables, the number and percentage of
patients in each category will be reported for each treat-
ment group and overall. Chi-squared tests will be utilised
for comparing the treatments, with additional analyses be-
ing undertaken using multi-variable logistic regression
with adjustment for stratification and other important
prognostic factors if sufficient events have been observed.
For the dual primary outcomes, a significance level of
0.025 (2.5%) will be used and 97.5% confidence intervals
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will be presented. All secondary analyses will be consid-
ered as supporting the primary analyses, and thus, a sig-
nificance level of 0.05 (5%) will be used and 95%
confidence intervals will be presented.
All principal analyses will be undertaken on an intent-
to-treat basis; that is, patients will be analysed as they
are randomised, with sensitivity analyses being under-
taken on the per-protocol population. The principal ana-
lyses will be performed for the available case dataset. For
each outcome variable, patterns of missing data will be
explored, and if there is a substantial amount of missing
data on either of the dual primary outcomes, a sensitivity
analysis using multiple imputation will explore the im-
pact of missing data on the results.
Health economic analysis
A cost utility analysis will be performed using patient-
reported quality of life, obtained using the EuroQol EQ-
5D-5 L questionnaire at baseline, on the evening of sur-
gery (day 0), on days 1, 2 and 3 following surgery and at
6 weeks, 6 months and 1 year. Following National Insti-
tute for Health and Care Excellence (NICE) recommen-
dations [25], the EQ-5D-5 L responses will be mapped
onto the EQ-5D-3 L valuation set to derive the utility
values [26]. Quality-adjusted life years (QALYs) will be
calculated using the area under the curve approach,
which involves estimating the average EQ-5D utility be-
tween each follow-up time weighted by survival time.
To estimate healthcare costs associated with knee re-
placement and trial drug, information will be collected
for each patient in the trial on the resources used during
the initial surgery (including time in theatre, type of
procedure, analgesic medication, complications and
length of stay) and on subsequent related healthcare use
(e.g. primary care visits, outpatient visits, hospital re-
admissions, etc.) over the first year following randomisa-
tion. Information will also be collected on out-of-pocket
expenses (e.g. over-the-counter medications, equipment,
travel costs to attend consultations, private practitioners,
etc.), impact on informal carers and loss of earnings
resulting from knee replacement.
The best practice methods will be followed to address
missing data in cost-effectiveness studies [27]. Descrip-
tive statistics (means, standard deviations) will be pro-
vided for resource use, costs and EQ-5D utilities in each
trial arm and at each follow-up time point. If appropri-
ate, we will estimate the incremental cost-effectiveness
ratio (ICER) by dividing the mean cost difference be-
tween trial arms by the mean QALY difference. Differ-
ences between trial arms will be estimated using linear
regression controlling for treatment allocation and the
same factors as used for the primary endpoints. Uncer-
tainty around the ICER will be determined using non-
parametric bootstrapping and presented graphically in a
cost-effectiveness scatter plot and cost-effectiveness ac-
ceptability curves [28].
Trial committees
A Data and Safety Monitoring Committee (DSMC) will be
appointed to safeguard the interests of the trial partici-
pants, to assess the safety and efficacy of the interventions
during the trial and to monitor the overall conduct of the
trial, protecting its validity and credibility. The DSMC will
not be asked to perform any formal interim analyses of ef-
fectiveness. The DSMC will be independent of the trial in-
vestigators and sponsor and will adopt a DAMOCLES
charter that defines its terms of reference and operation in
relation to oversight of the trial. The DSMC may advise
the chair of the Trial Steering Committee (TSC) at any
time if, in its view, the trial should be stopped for ethical
reasons. The DSMC will comprise two independent med-
ically qualified clinicians and a statistician.
A TSC will also be appointed whose primary function
is to act as an oversight body for the trial on behalf of
the sponsor and funding body. The TSC will be chaired
by an independent member and act as appropriate on
the recommendations of the DSMC. The TSC ultimately
carries responsibility for deciding if the trial needs to be
stopped on the grounds of safety.
Dissemination
The trial results will be disseminated, regardless of the
magnitude or direction of effect, to key stakeholders and
patients in several ways: peer-reviewed, open-access
journals; funder reports; presentations at key scientific
meetings, made available on specialist websites; feedback
to trial participants; press releases at collaborating insti-
tutions; and cooperation with the patient representatives
to disseminate to the wider public.
The criteria for authorship will be taken from the
International Committee of Medical Journal Editors.
Those who do not meet the authorship criteria but con-
tributed to aspects of the study design or drafting of
work will be acknowledged as contributors. Those who
were solely involved in trial conduct (e.g. staff at recruit-
ing sites) will be acknowledged as collaborators.
Discussion
This research will further knowledge of the use of
opioid-sparing techniques in the management of patients
undergoing knee replacement surgery. Clinical and cost
effectiveness of the liposomal bupivacaine intervention
will be considered. Results may influence post-operative
patient management regimes.
Trial status
The first patient was randomised to the trial in March
2018. Recruitment for the study is ongoing and is
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expected to finish in February 2020. This paper is based
on the latest version of the protocol, v5 dated November
2018.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-019-3826-1.
Additional file 1. SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents*.
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